BioLargo, Inc. / Fundamentals
Income statement
- Net revenue
€11.99M - Cost of goods sold
€6.54M - Gross profit
€5.44M - SG&A expenses
€8.46M - R&D expenses
€2.39M - EBITDA
-€5.21M - D&A
€184.24K - EBIT
-€5.41M - Interest expenses
€121.97K - EBT
-€4.97M - Tax expenses
€311.33K - Net income
-€3.32M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€675.54K - Changes in working capital
-€2.44M - Operating cash flow
-€6.38M - Capex
-€1.06M - Other investing cash flow
-€980.89K - Net investing cash flow
€81.88K - Total cash dividends paid
-€220.91K - Issuance of common stock
€2.62M - Debt repayment
€1.34M - Other financing cash flow
€2.54M - Net financing cash flow
€5.16M - Foreign exchange effects
€50.32K - Net change in cash
-€1.10M - Cash at end of period
€2.96M - Free cash flow
-€7.45M
Balance sheet
- Cash and cash equivalents
€2.96M - Cash and short-term investments
€2.96M - Total receivables
€4.45M - Inventory
€378.71K - Other current assets
€43.50K - Total current assets
€7.84M - Property, plant & equipment
€2.58M - Goodwill
€0.00 - Intangible assets
€29.00K - Long-term investments
€19.62K - Other non-current assets
€201.30K - Total non-current assets
€2.82M - Total assets
€10.66M - Accounts payable
€1.35M - Short-term debt
€1.12M - Other current liabilities
€1.02M - Total current liabilities
€3.48M - Long-term debt
€2.01M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€2.01M - Total liabilities
€5.49M - Common stock
€174.85K - Retained earnings
-€129.52M - Other equity
-€173.15K - Total equity
€5.17M - Total liabilities and shareholders' equity
€10.66M
Company information
- Market capitalization
€50.96M - Employees
40 - Enterprise Value
€59.95M
Company ratios
- Gross margin
-
45.4% Much better than peer group: 19.1% - EBITDA margin
-
-43.5% Much better than peer group: -141.5% - EBIT margin
-
-45.1% Much worse than peer group: 54.0% - EBT margin
-
-41.5% Much better than peer group: -218.4% - Net margin
-
-27.7% Much better than peer group: -199.8% - ROE
-
-64.3% Much worse than peer group: 33.1% - ROA
-
-31.2% Much better than peer group: -28,003.6% - Asset turnover
-
112.4% Much better than peer group: 37.0% - FCF margin
-
-44.4% Much better than peer group: -223.6% - FCF yield
-10.4% - Efficiency ratio
143.5% - Net sales per employee
-
€299.68K - Net income per employee
-
-€83.12K